Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum for Inflammation & Immunology and Metabolism, Showcasing Haduvio™ for Chronic Cough in IPF and RCC

Trevi Therapeutics (TRVI) will participate in the Leerink Partners Therapeutics Forum on July 8-9 in Boston. The company is developing Haduvio™ for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Senior management, including President and CEO Jennifer Good, and CFO Lisa Delfini, will attend the event. Haduvio™ has shown significant results in reducing cough frequency in clinical trials and is proposed as a promising therapy for these debilitating conditions.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, has announced that its President and CEO, Jennifer Good, and Chief Financial Officer, Lisa Delfini, will be attending the Leerink Partners Therapeutics Forum: I&I and Metabolism, scheduled for July 8-9 in Boston, Massachusetts [1][2][3].

The company is developing Haduvio™ (oral nalbuphine ER), an investigational therapy designed to treat chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio™ has shown statistically significant results in reducing cough frequency in clinical trials, making it a promising therapy for these debilitating conditions [1][2][3].

Chronic cough is a highly prevalent condition, affecting up to 85% of IPF patients, with approximately 150,000 patients in the U.S. suffering from IPF. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day, leading to worsening disease, higher risk of progression, death, or need for lung transplant. There are no approved therapies for chronic cough in IPF, and current off-label treatment options provide minimal benefit [1][2][3].

Refractory chronic cough, affecting around 2-3 million patients in the U.S., is defined as a persistent cough lasting over eight weeks despite treatment for an underlying condition. It is a highly debilitating disease with a wide range of complications, including urinary incontinence, sleep disruption, and social embarrassment [1][2][3].

Trevi Therapeutics intends to propose Haduvio™ as the trade name for oral nalbuphine ER. The safety and efficacy of the therapy have not been evaluated by any regulatory authority [1][2][3].

References:
[1] https://ir.trevitherapeutics.com/2025-07-01-Trevi-Therapeutics-to-Attend-Leerink-Partners-Therapeutics-Forum-I-I-and-Metabolism
[2] https://www.morningstar.com/news/pr-newswire/20250701ny21369/trevi-therapeutics-to-attend-leerink-partners-therapeutics-forum-ii-and-metabolism
[3] https://www.prnewswire.com/news-releases/trevi-therapeutics-to-attend-leerink-partners-therapeutics-forum-ii-and-metabolism-302494927.html